- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04210713
Neuroimmune Dysfunction in Alcohol Use Disorder
November 30, 2023 updated by: Daniel Roche, University of Maryland, Baltimore
Characterization of Neuroimmune Dysfunction in Alcohol Use Disorder
The objective of this proposal is to advance medication development for alcohol use disorder by examining the efficacy and mechanisms of action of minocycline, a neuroimmune modulator, as a potential treatment.
This study has important clinical implications, as the available treatments for alcohol use disorder are only modestly effective and testing novel medications is a high research priority.
Study Overview
Status
Completed
Conditions
- Substance-Related Disorders
- Chemically-Induced Disorders
- Pathologic Processes
- Alcohol Drinking
- Drinking Behavior
- Alcoholism
- Alcohol-Related Disorders
- Inflammation
- Neurocognitive Disorders
- Disease
- Cognitive Dysfunction
- Mental Disorder
- Anti-Bacterial Agents
- Anti-Infective Agents
- Minocycline
- Cognition Disorder
Intervention / Treatment
Detailed Description
The research objective of this project is to characterize the role of the neuroimmune system in alcohol use disorder (AUD).
The proposed study employs a randomized, double-blind, and placebo-controlled design to examine how neuroinflammation, as measured via neuroimaging [e.g., magnetic resonance imaging (MRI)], relates to alcohol craving, neurocognitive impairment (e.g., memory, attention, etc.), and alcohol use in non-treatment seeking individuals with AUD.
The study will also determine whether minocycline (MINO), an FDA-approved antibiotic medication, affects any of the above listed measures.
In the proposed study, healthy controls (n = 36) and non-treatment seeking individuals with a current Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 AUD diagnosis (n = 36) will be randomized to receive either 200 mg of minocycline per day or placebo for approximately 28 days and complete two laboratory sessions.
The first laboratory session will be performed immediately before commencing the medication regimen (day 0) and the second will be completed after taking the medication daily for approximately 28 days.
Within each laboratory session, participants will complete a cue reactivity paradigm, neurocognitive performance tasks, and a magnetic resonance imaging (MRI) session.
Additionally, blood samples will be drawn on days 0, 7, 14, 21, and 28 of treatment to measure circulating levels of proinflammatory molecules in order to identify the specific immune signaling pathways underlying neuroinflammation in AUD.
Clinical labs (e.g., blood chemistry, liver function tests) and adverse events (AEs) will also be assessed at these five visits.
Study Type
Interventional
Enrollment (Actual)
142
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Brian Brandler, MA
- Phone Number: 410-402-6425
- Email: bbrandler@som.umaryland.edu
Study Contact Backup
- Name: Ann Kearns, BS
- Phone Number: 410-402-6854
- Email: akearns@mprc.umaryland.edu
Study Locations
-
-
Maryland
-
Catonsville, Maryland, United States, 21228
- Maryland Psychiatric Research Center (MPRC) Treatment Research Program (TRP)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
23 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
AUD Group Inclusion Criteria:
- Meet DSM-5 diagnostic criteria for an AUD
- In the 30-day period before enrollment, consume ≥ 14 and ≥ 7 standard drinks per week for men and women, respectively, AND
- In the 30-day period before enrollment, engage in heavy drinking (5 or more drinks for men, 4 or more drinks for women) and ≥ 5 times per month
AUD Group Exclusion Criteria:
- Currently in treatment for AUD, a history of treatment within the 30 days before enrollment, or currently seeking immediate treatment
- Current (last 12 months) DSM-5 diagnosis of substance use disorder for any psychoactive substances other than alcohol and nicotine
- Currently prescribed a psychotropic medication for the treatment of schizophrenia spectrum and other psychotic disorders, bipolar and related disorders, depressive disorders, anxiety disorders, and mood disorders.
- Lifetime DSM-5 diagnosis of schizophrenia spectrum and other psychotic disorders and bipolar and related disorders
- Positive urine toxicology screen for the following substances: cocaine, opiates, amphetamines, methamphetamine, phencyclidine, barbiturates, benzodiazepine, methadone, and tricyclic antidepressants.
- Self-reported daily use of cannabidiol (CBD) or opioids (including prescribed)
- Serious alcohol withdrawal symptoms as indicated by a score ≥ 10 on the Clinical Institute Withdrawal Assessment for Alcohol-Revised
- If female: pregnancy, nursing, or refusal to use reliable method of birth control; if using hormonal contraceptives, refusal to use secondary birth control method
- Any autoimmune or inflammatory medical disorder or medical condition that may interfere with safe study participation and/or study aims (e.g., unstable cardiac, renal, or liver disease, uncontrolled hypertension or diabetes)
- Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or γ-glutamyl transferase (GGT) ≥ 4 times upper normal limit
- Attempted suicide in the past 3 years and/or serious suicidal intention or plan within the past year
- Currently on prescription medication that contraindicates use of minocycline, including but not necessarily limited to: isoretinoin, ergot alkaloids, and anti-coagulants.
- Previously known hypersensitivity to tetracyclines
- Current or recent (within one month) treatment with any antibiotic
- Regular use of a prebiotic or probiotic supplement
- Claustrophobia or physical issues preventing MRI scan
- Presence of a metal device in the body (e.g., pacemaker, infusion pump, aneurysm clip, metal prosthesis or plate)
- Current or recent (within 3 months) participation in a clinical trial involving medication administration
- Suffered a mild or moderate traumatic brain injury (TBI) within the last 12 months, a severe TBI at any point in their life, or a moderate TBI before the age of 12.
- Having below a 6th grade reading level
- Within the last 3 months, tested positive for COVID-19 (i.e. the SARS-CoV-2 virus) and experienced common related symptoms.
- Any other circumstances that, in the opinion of the investigators, compromises participant safety, ability of the investigators to conduct the study as designed, and/or study integrity.
Healthy Control Group Inclusion Criteria:
- Does not meet DSM-5 diagnostic criteria for an AUD (current or lifetime)
- In the 30-day period before enrollment, consume ≤ 14 and ≤ 7 standard drinks per week for men and women, respectively
- Engage in infrequent heavy drinking during the past 6 months (≤ 2 heavy drinking events in past 6 months)
Healthy Control Group Exclusion Criteria:
- Lifetime DSM-5 diagnosis of substance use disorder for any psychoactive substances other than nicotine
- Self-reported daily use of cannabidiol (CBD) or opioids (including prescribed)
- Lifetime DSM-5 diagnosis of schizophrenia spectrum and other psychotic disorders, bipolar and related disorders, depressive disorders, anxiety disorders (panic disorder, agoraphobia, social anxiety, and generalized anxiety), obsessive-compulsive and related disorders, trauma- and stressor-related disorders, feeding and eating disorders (binge eating, anorexia, and bulimia), conduct disorders, and gambling disorder
- Positive urine toxicology screen for the following substances: cocaine, opiates, amphetamines, methamphetamine, phencyclidine, barbiturates, benzodiazepine, methadone, and tricyclic antidepressants.
- Serious alcohol withdrawal symptoms as indicated by a score ≥ 10 on the Clinical Institute Withdrawal Assessment for Alcohol-Revised
- If female: pregnancy, nursing, or refusal to use reliable method of birth control; if using hormonal contraceptives, refusal to use secondary birth control method
- Any autoimmune or inflammatory medical disorder or medical condition that may interfere with safe study participation and/or study aims (e.g., unstable cardiac, renal, or liver disease, uncontrolled hypertension or diabetes)
- Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or γ-glutamyl transferase (GGT) ≥ 4 times upper normal limit
- Attempted suicide in the past 3 years and/or serious suicidal intention or plan within the past year
- Currently on prescription medication that contraindicates use of minocycline, including but not necessarily limited to: isoretinoin, ergot alkaloids, and anti-coagulants.
- Previously known hypersensitivity to tetracyclines
- Current or recent (within one month) treatment with any antibiotic
- Regular use of a prebiotic or probiotic supplement
- Claustrophobia or physical issues preventing MRI scan
- Presence of a metal device in the body (e.g., pacemaker, infusion pump, aneurysm clip, metal prosthesis or plate)
- Current or recent (within 3 months) participation in a clinical trial involving medication administration
- Suffered a mild or moderate traumatic brain injury (TBI) within the last 12 months, a severe TBI at any point in their life, or a moderate TBI before the age of 12.
- Having below a 6th grade reading level
- Within the last 3 months, tested positive for COVID-19 (i.e. the SARS-CoV-2 virus) and experienced common related symptoms.
- Any other circumstances that, in the opinion of the investigators, compromises participant safety, ability of the investigators to conduct the study as designed, and/or study integrity.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: AUD-Minocycline
Participants diagnosed with alcohol use disorder will be randomly assigned to take minocycline for 4 weeks.
The randomization is double-blinded and will alternate between minocycline and placebo.
|
200 mg/day
|
Placebo Comparator: AUD-Placebo
Participants diagnosed with alcohol use disorder will be randomly assigned to take placebo for 4 weeks.
The randomization is double-blinded and will alternate between minocycline and placebo.
|
Matched placebo
Other Names:
|
Active Comparator: Healthy Control-Minocycline
Healthy control participants will be randomly assigned to take minocycline for 4 weeks.
The randomization is double-blinded and will alternate between minocycline and placebo.
|
200 mg/day
|
Placebo Comparator: Healthy Control-Placebo
Healthy control participants will be randomly assigned to take placebo for 4 weeks.
The randomization is double-blinded and will alternate between minocycline and placebo.
|
Matched placebo
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Neuroinflammation
Time Frame: Change from baseline after 28 days of medication dosing
|
A multimodal MRI approach consisting of Diffusion Tensor Imaging (DTI) with free water imaging and Magnetic Resonance Spectroscopy (MRS) will be utilized to assess neuroinflammation
|
Change from baseline after 28 days of medication dosing
|
Cue-Induced Alcohol Craving
Time Frame: Change from baseline after 28 days of medication dosing
|
Participants will listen to a 5-minute guided cue exposure script, during which they are exposed to both a neutral and their preferred alcoholic beverage.
Prior to beginning the paradigm and after each cue exposure participants will rate their alcohol craving using the "Alcohol Urge Questionnaire (AUQ)" and cigarette craving using the "Brief Questionnaire on Smoking Urges (BQSU)."
Both scales range from 1 to 7 with higher scores reflecting more craving.
|
Change from baseline after 28 days of medication dosing
|
Alcohol consumption
Time Frame: Change from baseline after 28 days of medication dosing
|
Total drinks consumed assessed using the Timeline Follow Back
|
Change from baseline after 28 days of medication dosing
|
Verbal Fluency/Language
Time Frame: Change from baseline after 28 days of medication dosing
|
Wechsler Abbreviated Scale of Intelligence (WASI)-Vocabulary, WASI-Similarities, Verbal Fluency (Animals), with higher scores indicating greater intellectual ability.
|
Change from baseline after 28 days of medication dosing
|
Speed of processing
Time Frame: Change from baseline after 28 days of medication dosing
|
Brief Assessment of Cognition in Schizophrenia (BACS)-Symbol Coding [scored by number of correct numerals (range: 0 -110)]
|
Change from baseline after 28 days of medication dosing
|
Speed of processing
Time Frame: Change from baseline after 28 days of medication dosing
|
Trail Making Test: Part A (scored by time to complete test with lower scores being better)
|
Change from baseline after 28 days of medication dosing
|
Speed of processing
Time Frame: Change from baseline after 28 days of medication dosing
|
Grooved Pegboard (scored as a sum of the total time, total number of drops, and the total number of pegs correctly placed in the board with higher scores corresponding to worse performance)
|
Change from baseline after 28 days of medication dosing
|
Working Memory
Time Frame: Change from baseline after 28 days of medication dosing
|
Wechsler Memory Scale (WMS)-Spatial Span (scored up to 32 correct series), Letter-Number Span (scored up to 30 correct series)
|
Change from baseline after 28 days of medication dosing
|
Attention
Time Frame: Change from baseline after 28 days of medication dosing
|
Continuous Performance Test
|
Change from baseline after 28 days of medication dosing
|
Problem Solving/Executive Functioning
Time Frame: Change from baseline after 28 days of medication dosing
|
Wisconsin Card Sorting Test-64
|
Change from baseline after 28 days of medication dosing
|
Inhibition/Impulsivity
Time Frame: Change from baseline after 28 days of medication dosing
|
Stop-Signal Reaction Time
|
Change from baseline after 28 days of medication dosing
|
Verbal Learning
Time Frame: Change from baseline after 28 days of medication dosing
|
Hopkins Verbal Learning Test
|
Change from baseline after 28 days of medication dosing
|
Visual Learning
Time Frame: Change from baseline after 28 days of medication dosing
|
Brief Visuospatial Memory Test [scoring is as follows, 1) Total recall: The sum of all valid items generated across learning trials 1-3, 2) Delayed recall: The number of valid items generated after a delay (trial 4), 3) Percent retained: Delayed recall score divided by the higher of trial 2 or 3 × 100, and 4) Recognition Discrimination Index: True positive responses minus false positive responses.]
|
Change from baseline after 28 days of medication dosing
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Peripheral Proinflammatory Marker levels
Time Frame: At baseline (day zero) and after 7, 14, and 21 and 28 days of medication dosing
|
Serum level of inflammatory molecules
|
At baseline (day zero) and after 7, 14, and 21 and 28 days of medication dosing
|
Alcohol Use Disorder Severity
Time Frame: At baseline (day zero) and after 28 days of medication dosing
|
Symptom count from the alcohol module for the Structured Clinical Interview for DSM-5
|
At baseline (day zero) and after 28 days of medication dosing
|
Gut microbiota
Time Frame: At baseline (day zero) and after 7, 14, and 21 and 28 days of medication dosing
|
Gut microbiota from stool samples using the following parameters: 1) diversity and evenness (Shannon, Simpson index) and 2) similarity (phylogenetic UniFrac distance, Jensen-Shannon divergence)
|
At baseline (day zero) and after 7, 14, and 21 and 28 days of medication dosing
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Daniel Roche, PhD, University of Maryland, Baltimore
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 3, 2020
Primary Completion (Actual)
September 20, 2023
Study Completion (Actual)
September 20, 2023
Study Registration Dates
First Submitted
December 17, 2019
First Submitted That Met QC Criteria
December 21, 2019
First Posted (Actual)
December 26, 2019
Study Record Updates
Last Update Posted (Actual)
December 1, 2023
Last Update Submitted That Met QC Criteria
November 30, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Substance-Related Disorders
- Alcohol Drinking
- Alcoholism
- Inflammation
- Mental Disorders
- Cognitive Dysfunction
- Cognition Disorders
- Alcohol-Related Disorders
- Pathologic Processes
- Neurocognitive Disorders
- Chemically-Induced Disorders
- Drinking Behavior
- Anti-Infective Agents
- Anti-Bacterial Agents
- Minocycline
Other Study ID Numbers
- HP-00080891
- 5K01AA026005-03 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Substance-Related Disorders
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA)CompletedSubstance-Related Disorders | Substance Use | Substance Use Disorders | Substance Abuse | Substance Dependence | Substance Related Problem
-
US Department of Veterans AffairsCompletedAlcoholism | Substance Use Disorders | Substance Abuse | Alcohol Abuse | Substance DependenceUnited States
-
VA Office of Research and DevelopmentRecruiting
-
National Institute on Drug Abuse (NIDA)CompletedSubstance-related Disorders
-
Norwegian University of Science and TechnologyCompletedSubstance-related DisordersNorway
-
University of Southern CaliforniaNational Institute on Drug Abuse (NIDA)Completed
-
University Hospital, Basel, SwitzerlandPsychiatric Hospital of the University of BaselCompleted
-
University of LuebeckFederal Ministry of Health, GermanyCompletedSubstance-related Disorders
-
University of Illinois at Urbana-ChampaignCompletedSubstance-related Disorders
-
University of NebraskaCompletedSubstance-related Disorders | Alcohol-related DisordersUnited States
Clinical Trials on Minocycline
-
Journey Medical CorporationDr. Reddy's Laboratories LimitedCompleted
-
State University of New York - Downstate Medical...RecruitingAsthma | Allergic RhinitisUnited States
-
Central South UniversityCompleted
-
OraPharmaCompleted
-
Rempex (a wholly owned subsidiary of Melinta Therapeutics...Innovative Medicines Initiative; Universitätsklinikum KölnTerminatedRenal Insufficiency, Chronic | Healthy Subjects | Renal Insufficiency, AcuteGermany
-
Johns Hopkins UniversityMakerere UniversityTerminatedHIV Infections | HIV-associated Cognitive ImpairmentUganda
-
University of PittsburghTerminated
-
Ain Shams Universityfaculty of pharmacy Tanta UniversityNot yet recruiting
-
University of South FloridaCompleted
-
Beijing Tiantan HospitalNeuroDawn Pharmaceutical Co., Ltd.RecruitingIschemic Stroke, AcuteChina